| Authors: |
Omar MI; Academic Urology Unit, University of Aberdeen, Aberdeen, UK. m.i.omar@abdn.ac.uk.; Guidelines Office, European Association of Urology, Arnhem, Netherlands. m.i.omar@abdn.ac.uk., MacLennan S; Academic Urology Unit, University of Aberdeen, Aberdeen, UK., Ribal MJ; Guidelines Office, European Association of Urology, Arnhem, Netherlands., Roobol MJ; Erasmus MC, Rotterdam, Netherlands., Dimitropoulos K; Academic Urology Unit, University of Aberdeen, Aberdeen, UK., van den Broeck T; Guidelines Office, European Association of Urology, Arnhem, Netherlands., MacLennan SJ; Academic Urology Unit, University of Aberdeen, Aberdeen, UK., Axelsson SE; Bayer AG, Berlin, Germany., Gandaglia G; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy., Willemse PP; Guidelines Office, European Association of Urology, Arnhem, Netherlands., Mastris K; European Cancer Patient Coalition, Brussels, Belgium., Ransohoff JB; Bayer AG, Berlin, Germany., Devecseri Z; Sanofi, Chilly-Mazarin, France., Abbott T; Astellas, Leiden, Netherlands., De Meulder B; Association EISBM, Vourles, France., Bjartell A; Department of Translational Medicine, Lund University, Lund, Sweden., Asiimwe A; Bayer AG, Berlin, Germany., N'Dow J; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.; Guidelines Office, European Association of Urology, Arnhem, Netherlands. |
